pde-3 Antibody

Introduction to PDE3 Antibody

Phosphodiesterase 3 (PDE3) antibodies are specialized immunological tools designed to detect and study PDE3 isoforms (PDE3A and PDE3B), which are enzymes critical for hydrolyzing cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in cellular signaling. These antibodies enable researchers to investigate PDE3 expression, localization, and function in diverse biological contexts, including cardiovascular regulation, inflammation, and metabolic disorders .

Anti-PDE3A Antibody (ab244337)

• Host Species: Rabbit monoclonal .

• Reactivity: Human, mouse, rat .

• Applications:

  • Immunohistochemistry (IHC): Staining of formalin-fixed, paraffin-embedded human heart tissue at a 1:50 dilution .

  • Immunocytochemistry (ICC): Detection in Triton X-100–permeabilized HeLa cells at 4 µg/mL .

  • Western Blot (WB): Recognizes a ~125 kDa band in HeLa and HEK-293 cell lysates .

Validation Data:

Role in Cardiac Hypertrophy

PDE3A antibodies (e.g., A302-740A and Sc-293446) were used to identify nuclear PDE3A2 as a regulator of cardiac myocyte hypertrophy. Key findings include :

• Nuclear Localization: Leptomycin B treatment increased nuclear PDE3A2 levels by 50%, confirmed via immunofluorescence and subcellular fractionation .

• Functional Impact: PDE3A2 degradation of cAMP in the nucleus protects against hypertrophic growth, while its inhibition triggers pathological remodeling .

Mast Cell and Inflammatory Studies

In allergic airway inflammation models, PDE3 antibodies helped quantify reduced epithelial mast cell numbers (Pde3 −/− mice) and validated PDE3 inhibitor effects on degranulation markers (e.g., CD63) .

Comparative Analysis of PDE3 Antibodies

Clinical and Therapeutic Implications

• Cardiovascular Disease: PDE3A antibodies have elucidated mechanisms in heart failure and arrhythmias, linking nuclear PDE3A2 activity to cAMP-dependent hypertrophy pathways .

• Allergic Inflammation: Studies using PDE3 inhibitors (e.g., enoximone) revealed reduced eosinophil recruitment and mast cell degranulation, suggesting therapeutic potential for PDE3-targeted therapies .

Technical Considerations

• Storage: Store at -20°C in aliquots to avoid freeze-thaw cycles .

• Controls: Include PDE3-deficient cell lysates (e.g., Pde3 −/− mice) to confirm specificity .

• Limitations: Cross-reactivity with PDE3B not fully ruled out in some commercial antibodies .